Glen Rock, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”),...
MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...
REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of...
NOVATO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for...
Licensed antigens are shared across major subsets of NSCLC and have confirmed presence on the surface of tumor cells, homogeneous...
– PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergyi,ii –...
Yossi Ben Amram Appointed President as Bio-AI Innovator Continues to Expand Roster of Influential Experts Guiding Its Global Growth Yossi...
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 - - IND...
Abstracts highlight the serious clinical burden of uncontrolled NASH and identify opportunities to improve patient careIn an analysis of patient...
Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024FARMINGTON HILLS, Mich., Jan. 04, 2024 (GLOBE NEWSWIRE)...
Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and...
-- Positioned for three Phase 3 trial readouts over the next 18 months -- -- Topline data expected from Phase...
LSTA1, the Company’s lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic...
Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that...
Poised for multiple meaningful catalysts in 2024 driven by strong clinical progress across large market programs in wet age-related macular...
Study with YUTIQ® has Surpassed Goal of 100 Patients EnrolledATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:...
Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024Company announces the hiring of long-time industry veteran Jed...
– Schizophrenia late-stage clinical program advances with positive topline Phase 3 data, successful ongoing enrollment in open label extension (OLE)...
ROCKVILLE, Md., Jan. 04, 2024 (GLOBE NEWSWIRE) -- OncoC4, Inc. (“OncoC4”), a late-stage biopharmaceutical company developing novel medicines for cancer,...
CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer...